ALOX5

Across TCGA pan-cancer cohorts, ALOX5 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ALOX5 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher ALOX5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ALOX5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, LAML, and LUSC are the cancer types where ALOX5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	III,IV	0.074	0.574	<.001	24	view →
LAML	DFS	Median	All	0.056	0.572	.001	12	view →
LUSC	OS	Median	III,IV	0.258	0.670	.025	9	view →
UCEC	OS	Median	All	0.966	0.650	.022	8	view →
STAD	DFS	Median	All	0.162	0.539	.016	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	OS	Median	II,III,IV	0.239	0.715	.035	3	view →
HNSC	OS	Median	All	0.276	0.662	.015	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ALOX5–ESCA (OS)

Open the ESCA breakdown →